Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting

A Multicenter, Randomized, Double-Blind, Crossover Study

Abstract

Objective: To compare the efficacy and side effects of ondansetron with those of high-dose metoclopramide in treating acute and delayed cisplatin-induced nausea and vomiting.

Design: Randomized, double-blind, crossover trial.

Setting: Conducted at two university hospitals, a cancer institute, and six community hospitals.

Patients: Of 125 patients, 95 were evaluable for the acute phase and 79 for the delayed phase. Major reasons for not being evaluable were no second course (14 patients), protocol violation (5 patients), and change in cisplatin dose (3 patients) for the acute phase, and rescue medication on day 1 (7 patients), protocol violation (3 patients), and inadequate data (4 patients) for the delayed phase.

Interventions: All patients received cisplatin, 50 to 100 mg/m2 body surface area (median, 75 mg/m2); none had previously received chemotherapy. Thirty minutes before the cisplatin administration, ondansetron was given intravenously over 15 minutes, at a loading dose of 8 mg followed by a continuous infusion of 1 mg/h for 24 hours. Metoclopramide was given at a loading dose of 3 mg/kg body weight, followed by a continuous infusion for 8 hours (4 mg/kg). For the delayed phase (days 2 through 6), the first oral dose was given as soon as the infusion was completed; the oral dose consisted of either metoclopramide, 20 mg three times daily, or ondansetron, 8 mg three times daily for another 5 days.

Measurements and Main Results: In the acute phase, a major or complete response was seen in 72% of the ondansetron-treated and 41% of the metoclopramide-treated patients (P < 0. 001). Nausea was significantly better controlled among the ondansetron-treated patients (P = 0.04). In the delayed phase, no statistically significant difference was seen between ondansetron- and metoclopramide-treated patients. Nausea was significantly better controlled with metoclopramide (P = 0.016).

Conclusions: Ondansetron is significantly more effective than metoclopramide in preventing acute nausea and vomiting. In the delayed phase, the results of both drugs were disappointing, although metoclopramide's effect on delayed nausea was superior. Patients preferred ondansetron.

Article and Author Information

  • From the University Hospital, Nijmegen, The Netherlands; Rotterdam Cancer Institute, Rotterdam, The Netherlands; the Free University Hospital, Amsterdam, The Netherlands; Maria Hospital, Tilburg, The Netherlands; and Glaxo Group Research Limited, Greenford, Great Britain. For current author addresses, see end of text.

  • Requests for Reprints: Pieter H. M. De Mulder, MD, Department of Medicine, Division of Medical Oncology, University Hospital, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

  • Current Author Addresses: Drs. De Mulder and van Liessum: Department of Medicine, Academic Hospital Nijmegen, P. O. Box 9101, 6500 HB Nijmegen, The Netherlands.

    Drs. Seynaeve and Verweij: Rotterdam Cancer Institute, P. O. Box 5201, 3008 AE Rotterdam, The Netherlands.

    Dr. Vermorken: Department of Medical Oncology, Free University Hospital, P. O. Box 7057, 1007 MB Amsterdam, The Netherlands.

    Dr. Mols-Jevdevic: Dr Deelenlaan 5, Maria Hospital, 5042 AD Tilburg, The Netherlands.

    Drs. Allman and Beranek: Glaxo Groups Research Limited, Greenford Road, Greenford, UB6 OHE, United Kingdom.

« Previous | Next Article »Table of Contents